Navigation Links
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Date:2/13/2009

MISSISSAUGA, ON, Feb. 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported operational and financial results for the second quarter of fiscal 2009, ended December 31, 2008.

"During the quarter we prepared to initiate our two randomized Phase II trials for nimotuzumab, which concentrate on two forms of cancer typically treated with radiation-containing regimens. These trials are the cornerstone of YM's registration program for this drug, driven by prior data indicating nimotuzumab's potential to maximize the benefits of radiotherapy while avoiding the toxic side-effects of the other EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "In addition to YM's internal clinical strategy, we continue to benefit from the network of cooperative relationships for the development of nimotuzumab which is undertaking a broad, late-stage, clinical program for this drug."

    Highlights for the second quarter of Fiscal 2009:

    -   YM received clearance from Canadian regulatory authorities to
        initiate two Phase II, double-blind, randomized trials for its EGFR-
        targeting antibody, nimotuzumab, in combination with radiation-based
        treatments. Enrolment for both trials, one in patients with non-small
        cell lung cancer (NSCLC) and the other in patients with brain
        metastases from NSCLC, is expected to be initiated in Canada in the
        first quarter of calendar 2009 and YM anticipates expanding the
        trials into other countries.
    -   The National Cancer Centre of Singapore (NCCS) selected nimotuzumab
        for evaluation in the adjuvant setting in a multinational Phase III
        trial of more than 700 patients with cancers of the head and neck,
        citing the drug's preferential safety profil
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
2. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
3. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
5. BD Biosciences to Distribute FCS Express
6. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
7. Cell Biosciences Introduces Kits for Oncoprotein Analysis
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Due to a misstatement posted by ... Adult Stem Cell Technology Center, LLC ( ASCTC ) was ... therapy research that might benefit ALS patients. Because of ... stem cell technologies and therapeutic applications, FRC listed ASCTC as ... donors who wish not to support research that requires ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)... TALLAHASSEE, Fla. Exciting new work by a Florida ... molecular system that can take your temperature, emit white ... , And, the molecule looks like a butterfly. , ... and Biomedical Engineering in the FAMU-FSU College of Engineering, ... ago, but has continued to discover that his creation ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... DIEGO and AUSTIN, Texas, Aug. 16 DJO Incorporated,(NYSE: ... services that promote,musculoskeletal and vascular health, today reported that ... granted early termination of the,waiting period under the Hart-Scott-Rodino ... acquisition of DJO by an affiliate of,ReAble Therapeutics, Inc. ...
... Technology,s Robert Lanza, MIT,s Robert ... Langer, and Harvard,s Joseph Vacanti, WORCESTER, Mass., ... medicine, Robert Lanza, M.D.,VP Research & Scientific Development for Advanced ... at MIT,(recent recipient of the National Medal of Science), and ...
... Sales Up 49%, Pre-Tax Net Income Up 42%, ... Inc. (OTC Bulletin Board: CKGT), a vertically integrated,grower, developer, ... today filed its report on Form 10QSB and reported ... All results reported,are in U.S. dollars. The Company ...
Cached Biology Technology:DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4New Edition of Definitive Resource in Tissue Engineering Released Today 2New Edition of Definitive Resource in Tissue Engineering Released Today 3China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results 2China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results 3
(Date:8/28/2014)... the University of Minnesota have developed an animal research ... for muscle regeneration research as well as studies of ... research is published in the current edition of the ... treatment for FSHD, which is thought by many to ... is an unusual genetic disorder because, unlike most genetic ...
(Date:8/28/2014)... unique method for delivering compounds that could ... and AIDS may be possible, thanks to ... Sciences., A semi-soft vaginal suppository made from ... with the antiviral drug Tenofovir provides a ... the spread of sexually transmitted infections during ...
(Date:8/28/2014)... new roads will be built worldwide by 2050. Many ... where they bring an influx of destructive loggers, hunters ... has created a ,global roadmap, for prioritising road building ... demands of development and environmental protection. , The map ... natural importance of ecosystems and a ,road-benefits, layer that ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Ohio Recent research that links specific pieces of ... lead the way to the prevention of viroids, pathogens ... plants. The findings and the research approach ... applications in the study of how certain viruses spread ...
... us have missed a dose of antibiotic or forgotten to ... as they are for people with HIV/AIDS a ... for the entire population. Now, a breath monitoring device ... Inc. could help prevent the emergence of drug-resistant strains of ...
... definitive critical review, scientists at Childrens Hospital & ... biological or behavioral evidence linking vitamin D deficiency ... staff scientist and Bruce N. Ames, Ph.D., senior ... conclude that there is ample biological evidence to ...
Cached Biology News:Analysis of RNA role in spreading disease advances study of damaging plant infections 2Analysis of RNA role in spreading disease advances study of damaging plant infections 3Analysis of RNA role in spreading disease advances study of damaging plant infections 4Scientists test device to track medication adherence in patients with HIV/AIDS 2Scientists test device to track medication adherence in patients with HIV/AIDS 3Vitamin D in brain function 2Vitamin D in brain function 3
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... (Cap Analog) is used for the synthesis ... vitro transcription reactions. Substitution of cap analog ... in an in vitro transcription reaction results ... into a large fraction of the transcripts. ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... atlantica Description: Beta-Agarase is useful in ... low-melting-temperature agarose. Beta-Agarase digests the agarose ... Friendly Properties: Heat Inactivation: 65C, 15 ... pH: 6.5 Purity: Tested for contaminating ...
Biology Products: